116 related articles for article (PubMed ID: 9469595)
41. Close correlation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate, an intracellular active metabolite, to the therapeutic efficacy of N(4)-behenoyl-1-beta-D-arabinofuranosylcytosine therapy for acute myelogenous leukemia.
Yamauchi T; Kawai Y; Goto N; Kishi S; Imamura S; Yoshida A; Urasaki Y; Fukushima T; Iwasaki H; Tsutani H; Masada M; Ueda T
Jpn J Cancer Res; 2001 Sep; 92(9):975-82. PubMed ID: 11572766
[TBL] [Abstract][Full Text] [Related]
42. Synthesis and evaluation of anti-tumor activities of N4 fatty acyl amino acid derivatives of 1-beta-arabinofuranosylcytosine.
Liu B; Cui C; Duan W; Zhao M; Peng S; Wang L; Liu H; Cui G
Eur J Med Chem; 2009 Sep; 44(9):3596-600. PubMed ID: 19321234
[TBL] [Abstract][Full Text] [Related]
43. Modulation of the effect of 1-beta-D-arabinofuranosylcytosine based on changes of cytidine deaminase activity in HL60 cells.
Mejer JN; Mortensen BT; Christensen IJ
Med Oncol Tumor Pharmacother; 1990; 7(1):25-9. PubMed ID: 2338846
[TBL] [Abstract][Full Text] [Related]
44. Treatment of L1210 murine leukemia with liposome-incorporated N4-hexadecyl-1-beta-D-arabinofuranosyl cytosine.
Schwendener RA; Schott H
Int J Cancer; 1992 May; 51(3):466-9. PubMed ID: 1592536
[TBL] [Abstract][Full Text] [Related]
45. Production of N4-succinyl-1-beta-D-arabinofuranosylcytosine, a novel metabolite of N4-behenoyl-1-beta-D-arabinofuranosylcytosine, in mice and its biological significance.
Oh-ishi J; Kataoka T; Tsukagoshi S; Sakurai Y; Shibukawa M; Kobayashi H
Cancer Res; 1981 Jun; 41(6):2501-6. PubMed ID: 7237444
[TBL] [Abstract][Full Text] [Related]
46. Therapeutic synergism of tiazofurin and selected antitumor drugs against sensitive and resistant P388 leukemia in mice.
Harrison SD; O'Dwyer PJ; Trader MW
Cancer Res; 1986 Jul; 46(7):3396-400. PubMed ID: 3708573
[TBL] [Abstract][Full Text] [Related]
47. Antitumor activity and novel DNA-self-strand-breaking mechanism of CNDAC (1-(2-C-cyano-2-deoxy-beta-D-arabino-pentofuranosyl) cytosine) and its N4-palmitoyl derivative (CS-682).
Hanaoka K; Suzuki M; Kobayashi T; Tanzawa F; Tanaka K; Shibayama T; Miura S; Ikeda T; Iwabuchi H; Nakagawa A; Mitsuhashi Y; Hisaoka M; Kaneko M; Tomida A; Wataya Y; Nomura T; Sasaki T; Matsuda A; Tsuruo T; Kurakata S
Int J Cancer; 1999 Jul; 82(2):226-36. PubMed ID: 10389757
[TBL] [Abstract][Full Text] [Related]
48. Lipophilic arabinofuranosyl cytosine derivatives in liposomes.
Schwendener R; Schott H
Methods Enzymol; 2005; 391():58-70. PubMed ID: 15721374
[TBL] [Abstract][Full Text] [Related]
49. [Antitumor activity of a novel analog of cytarabine, 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone 5'-(sodium octadecyl phosphate) monohydrate (YNK01)].
Nagahata T; Shibasaki C; Ishii T; Uchida T; Arakawa M; Kusama K; Ekimoto H; Takahashi K
Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1437-45. PubMed ID: 2389942
[TBL] [Abstract][Full Text] [Related]
50. Lipophilic 5'-(alkyl phosphate) esters of 1-beta-D-arabinofuranosylcytosine and its N4-acyl and 2,2'-anhydro-3'-O-acyl derivatives as potential prodrugs.
Rosowsky A; Kim SH; Ross J; Wick MM
J Med Chem; 1982 Feb; 25(2):171-8. PubMed ID: 7057424
[TBL] [Abstract][Full Text] [Related]
51. Combination effects of Ara-C and 5-fluorodeoxyuridine against leukemia cells in vitro and in mice.
Rauko P; Bauer W; Horvath Z; Höchtl T; Saiko P; Karl D; Schott H; Fritzer-Szekeres M; Novotny L; Szekeres T
Anticancer Res; 2003; 23(5A):3841-6. PubMed ID: 14666686
[TBL] [Abstract][Full Text] [Related]
52. Effect and mode of action of N4-behenoyl-beta-D-arabinofuranosylcytosine.
Kataoka T; Sakurai Y
Recent Results Cancer Res; 1980; 70():147-51. PubMed ID: 7355245
[TBL] [Abstract][Full Text] [Related]
53. The treatment of intravenously implanted Lewis lung carcinoma with two sustained release forms of 1-beta-D-arabinofuranosylcytosine.
Rahman YE; Patel KR; Cerny EA; Maccoss M
Eur J Cancer Clin Oncol; 1984 Aug; 20(8):1105-12. PubMed ID: 6540691
[TBL] [Abstract][Full Text] [Related]
54. Synthesis and antiproliferative potency of 9-beta-D-arabinofuranosyl-2-fluoroadenine phospholipid adducts.
Brachwitz H; Bergmann J; Thomas Y; Wollny T; Langen P
Bioorg Med Chem; 1999 Jun; 7(6):1195-200. PubMed ID: 10428391
[TBL] [Abstract][Full Text] [Related]
55. Intracellular pharmacodynamic studies of the synergistic combination of 6-mercaptopurine and cytosine arabinoside in human leukemia cell lines.
Ramilo-Torno LV; Avramis VI
Cancer Chemother Pharmacol; 1995; 35(3):191-9. PubMed ID: 7805176
[TBL] [Abstract][Full Text] [Related]
56. [Antitumor effects of Behenoyl-ara-C (BH-AC) in combination with Idarubicin (IDA) in P 388 leukemic cell bearing mice].
Watanabe A; Kuriyama H; Kiyota T
Gan To Kagaku Ryoho; 1996 Feb; 23(3):291-6. PubMed ID: 8712821
[TBL] [Abstract][Full Text] [Related]
57. Development of resistance to 1-beta-D-arabinofuranosylcytosine after high-dose treatment in childhood lymphoblastic leukemia: analysis of resistance mechanism in established cell lines.
Kees UR; Ford J; Dawson VM; Piall E; Aherne GW
Cancer Res; 1989 Jun; 49(11):3015-9. PubMed ID: 2720661
[TBL] [Abstract][Full Text] [Related]
58. Nucleoside conjugates as potential antitumor agents. 3. Synthesis and antitumor activity of 1-(beta-D-arabinofuranosyl)cytosine conjugates of corticosteroids.
Hong CI; Nechaev A; Kirisits AJ; Buchheit DJ; West CR
J Med Chem; 1980 Dec; 23(12):1343-7. PubMed ID: 7452687
[TBL] [Abstract][Full Text] [Related]
59. Nucleic acids. 16. Orally active derivatives of ara-cytidine.
Wechter WJ; Gish DT; Greig ME; Gray GD; Moxley TE; Kuentzel SL; Gray LG; Gibbons AJ; Griffin RL; Neil GL
J Med Chem; 1976 Aug; 19(8):1013-7. PubMed ID: 966247
[TBL] [Abstract][Full Text] [Related]
60. Opposite effects on cytosolic Ca2+ of antitumor phospholipids by induction of calcium influx and activation of endoplasmic reticulum Ca(2+)-ATPase.
Bergmann J; Langen P; Thomas Y; Brachwitz H
Cell Calcium; 1998 Apr; 23(4):241-9. PubMed ID: 9681187
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
